Physiopathology of ALS: Therapeutic approach;Physiopathologie de la Sclérose Latérale Amyotrophique: Approches thérapeutiques

Revue Neurologique

Volumn 160, Issue 2, 2004, Pages 235-241

  Bruneteau, G ^a   Demeret, S ^a   Meininger, V ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; AMPA RECEPTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; CALCIUM; CELECOXIB; CILIARY NEUROTROPHIC FACTOR; COPPER ZINC SUPEROXIDE DISMUTASE; CYCLOOXYGENASE 2; EXCITOTOXIN; FIBROBLAST GROWTH FACTOR; GABAPENTIN; GLUTAMATE RECEPTOR; GLUTAMATE RECEPTOR 1; GLUTAMIC ACID; GROWTH FACTOR; ISOLEUCINE; LEUCINE; MINOCYCLINE; NEUROTROPHIC FACTOR; OSTEOGENIC PROTEIN 1; PEPTIDE DERIVATIVE; PROTEIN G; RILUZOLE; ROFECOXIB; SCATTER FACTOR; SOMATOMEDIN C; TOPIRAMATE; UNINDEXED DRUG; VALINE; XALIPRODEN;

AMINO ACID METABOLISM; AMYOTROPHIC LATERAL SCLEROSIS; APOPTOSIS; CALCIUM METABOLISM; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; GENE MUTATION; HUMAN; LEWY BODY; META ANALYSIS; MITOCHONDRION; MOTONEURON; NERVE CELL DEGENERATION; NEUROFILAMENT; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PATHOPHYSIOLOGY;

EID: 1542284184     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0035-3787(04)70897-8     Document Type: Conference Paper

References (62)

1. ALMER G, GUÉGAN C, TEISMANN P, et al. (2001). Increased expression of the pro-inflammatory enzyme cyclooxygenase-2 in amyotrophic lateral sclerosis. Ann Neurol, 49: 176-185.
2. ARMON C, GUILOFF RJ, BEDLACK R. (2002). Limitations of inferences from observational databases in amyotrophic lateral sclerosis: all that glitters is not gold. Amyotroph Lateral Scler Other Motor Neuron Disord, 3: 109-111.
3. BARDE YA. (1989). Trophic factors and neuronal survival. Neuron, 2: 1525-1534.
4. BARBACID M. (1994). The Trk family of neurotrophin receptors. J Neurobiol, 25: 1386-1403.
5. BDNF STUDY GROUP. (1999). Controlled Trial of Recombinant-Methionyl BDNF (r-metHuBDNF) in ALS. Neurology, 52: 1427-1433.
6. 10 as a possible treatment for neurodegenerative diseases. Free Radic Res, 36: 455-460.
7. BENSIMON G, LACOMBLEZ L, MEININGER V AND THE ALS/RILUZOLE STUDY GROUP. (1994). A controlled trial of Riluzole in amyotrophic lateral sclerosis. N Engl J Med, 330: 585-591.
8. BERGER MM, KOPP N, VITAL C, REDL B, AYMARD M, LINA B. (2000). Detection and cellular localization of enterovirus RNA sequences in spinal cord of patients with ALS. Neurology, 54: 20-25.
9. BERGERON C. (1995). Oxidative stress: Its role in the pathogenesis of amyotrophic lateral sclerosis. J Neurol Sci, 129: 81-84.
10. BONNEFONT-ROUSSELOT D, LACOMBLEZ L, JAUDON MC, et al. (2000). Blood oxidative stress in amyotrophic lateral sclerosis. J Neurol Sci, 178: 57-62.
11. BORASlO GD, ROBBERECHT W, LEIGH PN, et al. (1998). A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. Neurology, 51: 583-586.
12. BOWLING AC, BEAL MF. (1995). Bioenergetic and oxidative stress in neurodegenerative diseases. Life Sci, 56: 1151-1171.
13. CAMU W, CORCIA P, JAFARI-SHLUEP NF. (2002). Génétique de la SLA. In: Sclérose latérale amyotrophique. Expression Santé pub, Paris, pp 25-30.
14. CEDARBAUM JM, CHAPMAN C, CHARATAN M, et al. (1995). The pharmacokinetics of subcutaneously administered recombinant human ciliary neurotrophic factor (rHCNTF) in patients with amyotrophic lateral sclerosis: relation to parameters of the acute-phase response. Clin Neuropharmacol, 18: 500-514.
15. CLUSKEY S, RAMSDEN DB. (2001). Mechanisms of neurodegeneration in amyotrophic lateral sclerosis. J Clin Pathol Mol Pathol, 54: 386-392.
16. COUILLARD-DESPRÉS S, ZHU QZ, WONG PC, PRICE DL, CLEVELAND DW, JULIEN JP. (1998). Protective effect of neurofilament heavy gene overexpression in motor neuron disease induced by mutant superoxide dismutase. Proc Natl Acad Sci USA, 95: 9626-9630.
17. CROW JP, YE YZ, STRONG M, KIRK M, BARNES S, BECKMAN JS. (1997). Superoxide dismutase catalyzes nitration of tyrosines by peroxynitrite in the rod and head domains of neurofilament-L. J Neurochem, 69: 1945-1953.
18. DESNUELLE C, DIB M, GARREL C, FAVIER A. (2001). A double-blind, placebo-controlled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS riluzole-tocopherol Study Group. Amyotroph Lateral Scler Other Motor Neuron Disord, 1: 9-18.
19. DOBLE A. (1999). The role of excitotoxicity in neurodegenerative disease: implications for therapy. Pharmacol Ther, 81: 163-221.
20. ELLIOTT JL. (2001). Cytokine upregulation in a murine model of familial amyotrophic lateral sclerosis. Mol Brain Res, 95: 172-178.
21. FIGLEWICZ DA, KRIZUS A, MARTINOLI MG, et al. (1994). Variants of the heavy neurofilament subunit are associated with the development of amyotrophic lateral sclerosis. Hum Mol Genet, 3: 1757-1761.
22. FLOWERS JM, POWELL JF, LEIGH PN, ANDERSEN P, SHAW CE. (2001). Intron 7 retention and exon 3 skipping EAAT2 mRNA variants are not associated with amyotrophic lateral sclerosis. Ann Neurol, 49: 643-649.
23. GUÉGN C, VILA M, ROSOKLIJA G, HAYS AP, PRZEDBORSKI S. (2001). Recruitment of the mitochondrial-dependent apoptotic pathway in amyotrophic lateral sclerosis. J Neurosci, 21: 6569-6576.
24. HEATH PR, SHAW PJ. (2002). Update on the glutamatergic neurotransmitter system and the role of excitotoxicity in amyotrophic lateral sclerosis. Muscle Nerve, 26: 438-458.
25. HIGGINS CMJ, JUNG CW, DING HL, XU ZS. (2002). Mutant Cu, Zn superoxide dismutase that causes motoneuron degeneration is present in mitochondria in the CNS. J Neurosci, 22: NIL1-NIL6.
26. HOWLAND DS, LIU J, SHE YJ, et al. (2002). Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS). Proc Natl Acad Sci USA, 99: 1604-1609.
27. JULIEN JP. (1995). A role for neurofilaments in the pathogenesis of amyotrophic lateral sclerosis. Biochem Cell Biol, 73: 593-597.
28. JULIEN JP. (1997). Neurofilaments and motor neuron disease. Trends Cell Biol, 7: 243-249.
29. JULIEN JP, BEAULIEU JM. (2000). Cytoskeletal abnormalities in amyotrophic lateral sclerosis: beneficial or detrimental effects? J Neurol Sci, 180: 7-14.
30. KAAL ECA, VLUG AS, VERSLEIJEN MWJ, KUILMAN M, JOOSTEN EAJ, BÄR PRD. (2000). Chronic mitochondrial inhibition induces selective motoneuron death in vitro: a new model for amyotrophic lateral sclerosis. J Neurochem, 74: 1158-1165.
31. KLIVENYI P, FERRANTE RJ, MATTHEWS RT, et al. (1999). Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nature Med, 5: 347-350.
32. LACOMBLEZ L, BENSIMON G, LEIGH PN, GUILLET PH, MEININGER V, THE ALS/RILUZOLE STUDY GROUP II. (1996). Dose-Ranging Study of riluzole in amyotrophic lateral sclerosis. Lancet, 347: 1425-1431.
33. LAI EC, FELICE KJ, et al. (1997). Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS/IGF-I Study Group. Neurology, 49: 1621-1630.
34. LOTZ B, BROOKS B, SANJAK M, et al. (1996). A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. Neurology, 46: 1244-1249.
35. LUOOLPH AC, MÜNCH C. (1999). Neurotoxic mechanisms of degeneration in motor neuron diseases. Drug Metab Rev, 31: 619-634.
36. MARIOTTI R, BENTIVOGLIO M. (2000). Activation and response to axotomy of microglia in the facial motor nuclei of G93A superoxide dismutase transgenic mice. Neurosci Lett, 285: 87-90.
37. MARTIN LJ. (1999). Neuronal death in amyotrophic lateral sclerosis is apoptosis: possible contribution of a programmed cell death mechanism. J Neuropathol Exp Neurol, 58:459-471.
38. McGEER PL, McGEER EG. (1998). Glial cell reactions in neurodegenerative diseases: pathophysiology and therapeutic interventions. Alzheimer Dis Assoc Disord, 12: S1-S6.
39. McGEER PL, McGEER EG. (2002). Inflammatory processes in amyotrophic lateral sclerosis. Muscle Nerve, 26: 459-470.
40. MEININGER V, SALACHAS F. (2000). Review of clinical trials. In: BROWN RH, MEININGER V, SWASH M eds. Amyotrophic lateral sclerosis. Dunitz pub. Londres, pp. 389-402.
41. MEININGER V. (2002). Database analyses: a reply. Amyotroph Lateral Scler Other Motor Neuron Disord, 3: 113.
42. MENZIES FM, COOKSON MR, TAYLOR RW, et al. (2002). Mitochondrial dysfunction in a cell culture model of familial amyotrophic lateral sclerosis. Brain, 125: 1522-1533.
43. MEYER T, MÜNCH C, LIEBAU S, et al. (1998). Splicing of the glutamate transporter EAAT2: a candidate gene of amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry, 65: 954.
44. MILLER RG, MOORE D, YOUNG LA, et al. (1996a). Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology, 47: 1383-1388.
45. MILLER RG, PETAJAN JH, BRYAN WW, et al. (1996b). A placebo-controlled trial of recombinant human ciliary neurotrophic (rhC-NTF) factor in amyotrophic lateral sclerosis. Ann Neurol, 39: 256-260.
46. MILLER RG, MOORE DH, GELINAS DF, et al. (2001). Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology, 56: 843-848.
47. PENN RD, KROIN JS, YORK MM, CEOARBAUM JM. (1997). Intrathecal ciliary neurotrophic factor delivery for treatment of amyotrophic lateral sclerosis (Phase I trial). Neurosurgery, 40: 94-99.
48. RIVIERE M, MEININGER V, ZEISSER PH, MUNSAT TH. (1998). An analysis of extended survival in patients with amyotrophic lateral sclerosis treated with riluzole. Arch Neurol, 55: 526-528.
49. ROBBERECHT W, VAN DEN BOSCH L. (1998). The pathogenesis of amyotrophic lateral sclerosis. Neurosci Res Commun, 23: 67-75.
50. ROTHSTEIN JD, VAN KAMMEN M, LEVEY AI, MARTIN LJ, KUNCL RW. (1995). Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol, 38: 73-84.
51. SATHASIVAM S, INCE PG, SHAW PJ. (2001). Apoptosis in amyotrophic lateral sclerosis: a review of the evidence. Neuropathol Appl Neurobiol, 27: 257-274.
52. SENDTNER M, DITTRICH F, HUGHES RA, THOENEN H. (1994). Actions of CNTF and neurotrophins on degenerating motoneurons: preclinical studies and clinical implications. J Neurol Sci, 124: 77-83.
53. SIMONIAN NA, COYLE JT. (1996). Oxidative stress in neurodegenerative diseases. Annu Rev Pharmacol Toxicol, 36: 83-106.
54. SHIBATA N, NAGAI R, UCHIDA K, et al. (2001). Morphological evidence for lipid peroxidation and protein glycoxidation in spinal cords from sporadic amyotrophic lateral sclerosis patients. Brain Res, 917: 97-104.
55. SPREUX-VAROQUAUX O, BENSIMON G, LACOMBLEZ L, et al. (2002). Glutamate levels in cerebrospinal fluid in amyotrophic lateral sclerosis: a reappraisal using a new HPLC method with coulometric detection in a large cohort of patients. J Neurol Sci, 193: 73-78.
56. STEWART A, SANDERCOCK J, BRYAN S, HYDE C, BARTON PM, FRY-SMITH A, BURLS A. (2001). The clinical effectiveness and CDSt-effectiveness of riluzole for motor neuron disease: a rapid and systematic review. Heath Technol Assessment, 5: 1-95.
57. TRANCHANT C, VIADER F. (2002). Physiopathologie de la SLA. In: Sclérose latérale amyotrophique. Expression Santé pub, Paris, pp 15-24.
58. TURNER MR, BAKKER M, SHAM P, SHAW CE, LEIGH PN, AL CHALABI A. (2002). Prognostic modelling of therapeutic interventions in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord, 1: 15-21.
59. VAN DEN BOSCH L, TILKIN P, LEMMENS G, ROBBERECHT W. (2002a). Minocycline delays disease onset and mortality in a transgenic model of ALS. Neuroreport, 13: 1067-1070.
60. VAN DEN BOSCH L, SCHWALLER B, VLEMINCKX V, et al. (2002b) Protective effect of parvalbumin on excitotoxic motor neuron death. Exp Neurol, 174: 150-161.
61. VUKOSAVIC S, STEFANIS L, JACKSON-LEWIS V, et al. (2000). Delaying caspase activation by Bcl-2: a clue to disease retardation in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurosci, 20: 9119-9125.
62. WONG NKY, STRONG MJ. (1998). Nitric oxide synthase expression in cervical spinal cord in sporadic amyotrophic lateral sclerosis. Eur J Cell Biol, 77: 338-343.